

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Thomas Nissl

Confirmation No. 7923

Application No. 10/573,948

Filed: May 1, 2007

For: REMOVABLE STENT

Group Art Unit: 3738

Examiner: Tiffany P. Shipmon

Attorney Docket No. 37621/51901

Date: October 25, 2010

INFORMATION DISCLOSURE STATEMENT

TO THE COMMISSIONER FOR PATENTS:

1. Pursuant to the duty of disclosure, documents listed on the accompanying Form PTO-1449 (or equivalent) are presented for the Examiner's consideration.
 - ☒ Copies of listed U.S. patents and U.S. patent application publications are not required for submission. (37 C.F.R. § 1.98(a)(2)(ii))
 - ☒ Copies of listed foreign patent documents and/or non-patent literature are enclosed. (37 C.F.R. § 1.98(a)(2))
 - ☐ Copies of the documents listed at (sheet/cite no.) _____ of the attached Form PTO-1449 (or equivalent) are omitted because (1) they are already of record in U.S. Patent Application No. _____, filed _____, on which this application relies for an earlier filing date under 35 U.S.C. § 120; and (2) any information disclosure statement filed in the prosecution of Application No. _____, complies with 37 CFR §§ 1.98(a) through (c). (37 C.F.R. § 1.98(d))
 - ☐ A copy of copending U.S. Patent Application No. _____, filed _____, for _____, listed at (sheet/cite no.) _____ of the attached Form PTO-1449 (or equivalent), ☐ is enclosed / ☐ is omitted. (Copy not required if available via IFW. 1287 OG 163 (Oct. 19, 2004).).
2. This information disclosure statement is being submitted (check box a., b., or c.):
 - a. ☒ Within three months of the filing date of a national application or entry of the national stage in an international application; or before the mailing of a first Office action on the merits; or before the mailing of a first Office

action after the filing of a request for continued examination under 37 CFR 1.114. (No statement under 37 CFR 1.97(e) is required.); or

- b. ☐ After the period set forth in paragraph 2a, but before the mailing date of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or ii.)
- i. ☐ The \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is paid herewith, or
- ii. ☐ A statement specified by 37 CFR 1.97(e) is set forth below; or
- c. ☐ After the mailing date of a final action or notice of allowance and on or before payment of the issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. Enclosed is the \$180.00 information disclosure statement processing fee set forth in 37 CFR 1.17(p).

3. Fee Payment

- a. ☐ A check in the amount of \$_____ is enclosed.
- b. ☐ Payment by credit card.
- c. ☐ Please charge our Deposit Account No. 502375 in the amount of \$_____.
- d. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with filing of these papers, or credit overpayment to Deposit Account No. 502375.

4. If a statement specified by 37 CFR 1.97(e) is required, the attorney or agent signing below hereby states that:

- ☐ each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- ☐ no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

5. ☒ A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is set forth below.

Respectfully submitted,

Merit Medical Systems, Inc.

By /Matthew S. Bethards/
Matthew S. Bethards
Registration No. 51,466

STOEL RIVES LLP
One Utah Center Suite 1100
201 S Main Street
Salt Lake City, UT 84111-4904
Telephone: (801) 328-3131
Facsimile: (801) 578-6999

Source: JP11057022A

PROBLEM TO BE SOLVED: To stop insertion and shape restitution and recover easily when an indwelling shape abnormality occurs, by providing ring recovery sections on both ends of the frame in an intravascular indweller intended for hemostasis, constriction control, and thrombus movement control by making a catheter indwell intravascularly. **SOLUTION:** An intravascular indweller is formed by providing a recovery section 2 at one or two ends of the frame 4 of an intravascular indweller. To use it, the frame 4 is wound around an insertion catheter and a fixing line is run to the clearance of the frame 4 and the recovery portion 2 and fixed to the insertion catheter. Then the insertion catheter is advanced along a guide wire and stopped at an intended portion. By pulling the fixing line extracorporally, the frame 4 is separated from the insertion catheter by it's own restitutive force and is retained intravascularly. To stop the restitution of the frame 4 and remove it extracorporally, the frame 4 is removed extracorporally by stopping pulling of the fixing line and pulling the insertion catheter extracorporally.